Literature DB >> 22950386

Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma.

Ayae Kanemoto1, Masashi Mizumoto, Toshiyuki Okumura, Hideto Takahashi, Takayuki Hashimoto, Yoshiko Oshiro, Nobuyoshi Fukumitsu, Takashi Moritake, Koji Tsuboi, Takeji Sakae, Hideyuki Sakurai.   

Abstract

BACKGROUND: Radiation-induced rib fracture has been reported as a late complication after external radiotherapy to the chest. The purpose of this study was to clarify the characteristics and risk factors of rib fracture after hypofractionated proton beam therapy (PBT).
MATERIAL AND METHODS: The retrospective study comprised 67 patients with hepatocellular carcinoma who were treated using PBT of 66 Cobalt-Gray-equivalents [Gy (RBE)] in 10 fractions. We analyzed the patients' characteristics and determined dose-volume histograms (DVHs) for the irradiated ribs, and then estimated relationships between risk of fracture and several dose-volume parameters. An irradiated rib was defined to be any rib included in the area irradiated by PBT as determined by treatment-planning computed tomography.
RESULTS: Among the 67 patients, a total of 310 ribs were identified as irradiated ribs. Twenty-seven (8.7%) of the irradiated ribs developed fractures in 11 patients (16.4%). No significant relationships were seen between incidence of fracture and characteristics of patients, including sex, age, tumor size, tumor site, and follow-up period (p ≥ 0.05). The results of receiver operating characteristic curve analysis using DVH parameters demonstrated that the largest area under the curve (AUC) was observed for the volume of rib receiving a biologically effective dose of more than 60 Gy(3 )(RBE) (V60) [The equivalent dose in 2 Gy fractions (EQD2); 36 Gy(3)] and the AUCs of V30 to V120 (EQD2; 18-72 Gy(3)) and Dmax to D(10 cm)(3) were similar to that of V60. No significant relationships were seen for DVH parameters and intervals from PBT to incidence of fracture.
CONCLUSION: DVH parameters are useful in predicting late adverse events of rib irradiation. This study identified that V60 was a most statistically significant parameter, and V30 to V120 and Dmax to D(10 cm)(3) were also significant and clinically useful for estimating the risk of rib fracture after hypofractionated PBT.

Entities:  

Mesh:

Year:  2012        PMID: 22950386     DOI: 10.3109/0284186X.2012.718094

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  11 in total

1.  Proton therapy for hepatocellular carcinoma.

Authors:  Ted C Ling; Joseph I Kang; David A Bush; Jerry D Slater; Gary Y Yang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

Review 2.  Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 3.  Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience.

Authors:  Masashi Mizumoto; Yoshiko Oshiro; Toshiyuki Okumura; Nobuyoshi Fukumitsu; Haruko Numajiri; Kayoko Ohnishi; Teruhito Aihara; Hitoshi Ishikawa; Koji Tsuboi; Hideyuki Sakurai
Journal:  Int J Part Ther       Date:  2016-03-24

Review 4.  Mechanisms and Review of Clinical Evidence of Variations in Relative Biological Effectiveness in Proton Therapy.

Authors:  Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-15       Impact factor: 8.013

Review 5.  Proton Therapy in the Management of Hepatocellular Carcinoma.

Authors:  Jana M Kobeissi; Lara Hilal; Charles B Simone; Haibo Lin; Christopher H Crane; Carla Hajj
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

6.  End-of-Range Radiobiological Effect on Rib Fractures in Patients Receiving Proton Therapy for Breast Cancer.

Authors:  Chia-Chun Wang; Aimee L McNamara; Jungwook Shin; Jan Schuemann; Clemens Grassberger; Alphonse G Taghian; Rachel B Jimenez; Shannon M MacDonald; Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-03-30       Impact factor: 7.038

7.  Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma.

Authors:  Tae Hyun Kim; Joong-Won Park; Bo Hyun Kim; Dae Yong Kim; Sung Ho Moon; Sang Soo Kim; Ju Hee Lee; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Chang-Min Kim
Journal:  Oncotarget       Date:  2017-12-19

8.  Proton beam therapy for a patient with large rhabdomyosarcoma of the body trunk.

Authors:  Daichi Takizawa; Yoshiko Oshiro; Masashi Mizumoto; Hiroko Fukushima; Takashi Fukushima; Hideyuki Sakurai
Journal:  Ital J Pediatr       Date:  2015-11-16       Impact factor: 2.638

9.  Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

Authors:  Ken Yoshida; Yuki Otani; Takayuki Nose; Eisaku Yoden; Shuuji Asahi; Iwao Tsukiyama; Takushi Dokiya; Toshiaki Saeki; Ichirou Fukuda; Hiroshi Sekine; Yu Kumazaki; Takao Takahashi; Tadayuki Kotsuma; Norikazu Masuda; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi
Journal:  J Contemp Brachytherapy       Date:  2018-06-30

10.  How small is TOO small? New liver constraint is needed- Proton therapy of hepatocellular carcinoma patients with small normal liver.

Authors:  Ching-Hsin Lee; Sheng-Ping Hung; Ji-Hong Hong; Joseph Tung-Chieh Chang; Ngan-Ming Tsang; Kun-Ming Chan; Jeng-Hwei Tseng; Shih-Chiang Huang; Shi-Ming Lin; Jau-Min Lien; Nai-Jen Liu; Chen-Chun Lin; Wei-Ting Chen; Wan-Yu Chen; Po-Jui Chen; Bing-Shen Huang
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.